Novo Nordisk to expand GLP-1 production in France

Novo Nordisk will invest $2.3 billion to expand manufacturing at its plant in Chartres, France. The project includes finished-drug production for products based on a glucagon-like peptide-1 (GLP-1) agonist, semaglutide, the active ingredient in two of its blockbusters. Last month, the company announced a $6 billion expansion at its plant in Kalundborg, Denmark, which makes GLP-1 products. Novo Nordisk has been straining to keep up with demand for semaglutide. Its Weygovy, a weight loss drug, and Ozempic, for type 2 diabetes, booked sales of $4.5 billion in the third quarter, a 37% increase over the same period last year.